PSIL
AdvisorShares Psychedelics ETF
PSIL is actively managed to provide exposure to the emerging global psychedelics industry.
International
EQUITY
Active
MANAGEMENT STYLE
7.4 M
ASSETS UNDER MGMT
99 bp
EXPENSES
Fund Basics
| Fund sponsor | AdvisorShares |
| Category | International |
| Asset class | Equity |
| Website | link... |
| Inception date | Sep 15, 2021 |
| Assets (mns) | $7 |
| Expense ratio | 99 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-Ended Fund |
| Distributions | Annually |
| Taxation | 1099 |
| Stock selection | Proprietary |
| Weighting | Proprietary |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| MIND MEDICINE INC ORDINARY SHARES | 12.8 % |
| NRX PHARMACEUTICALS INC ORDINARY SHARES | 7.7 % |
| CYBIN INC ORDINARY SHARES | 7.4 % |
| ATAI LIFE SCIENCES N.V. | 6.4 % |
| ALKERMES PLC | 6.3 % |
| INCANNEX HEALTHCARE INC. | 5.2 % |
| VISTAGEN THERAPEUTICS INC | 4.7 % |
| NEUROCRINE BIOSCIENCES INC | 4.6 % |
| INTRA-CELLULAR THERAPIES INC | 4.5 % |
| COMPASS PATHWAYS PLC ADR | 4.5 % |
Constituent Breakdown
| Number of holdings | 28 |
| Herfindahl-Hirschman Index | 554 |
| Wgt avg mkt cap (mns) | $1,262 |
| Large cap (>$10bn) | 13.5% |
| Mid cap ($2-10bn) | 31.7% |
| Small cap (<$2bn) | 39.6% |
| Developed mkts. | 100.0% |
| Emerging mkts. | 0.0% |
Country Exposure
 |
UNITED STATES | 14.9 % |
 |
GERMANY | 6.4 % |
 |
IRELAND | 6.3 % |
 |
CANADA | 1.2 % |
Historical Performance
Standardized Performance (as of 12/31/2024)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | Incep. | |
|---|---|---|---|---|---|---|---|
| Total Returns | -21.0% | -21.0% | -23.0% | -42.1% | -- | -- | -48.9% | Volatility | 116.8% | 108.4% | 80.4% | 72.0% | -- | -- | -- |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.88 | 8% |
| MSCI EAFE | 0.45 | 2% |
| MSCI Emg Mkts | 0.57 | 3% |
Liquidity Measures
| Avg. volume (000) | 11 |
| Turnover | 1.9% |
| Avg. Bid/Ask (% of price) | 1.44% |
| ADV of underlying (mns) | $159 |
Technical Indicators
| Recent close | $12.82 |
| 30d moving avg. | $11.30 |
| Annualized volatility | 56.0% |
| Relative strength (RSI) | 57 |
| Short interest (ETF) | 8.2% |
| Short interest (underlying) | 0.0% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PSIL |
Expenses vs. PSIL |
ALTAR Score™ vs. PSIL |
|---|---|---|---|---|
| IBRN | iShares Neuroscience and Healthcare ETF | 12.8% | -52 bp | +0.3% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 11.5% | -43 bp | +8.4% |
Risk and Returns: PSIL vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
EPS Revision Activity (6 mo. ago = 100%)
Compound Annual Growth Rates
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| 2023 | 2024E | Fwd Est | 2025E | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 1/17/2025
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
PSIL
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
AVOID
Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may be less relevant.
ALTAR Score™
PSIL
-5.5%
Cat. Avg
7.2%
ALTAR Score™ Calculation
Category Overview
There are 265 funds in the International Equity category, with an average ALTAR Score™
of 7.2% and a standard deviation of
2.7%. PSIL's ALTAR Score™ is approximately
4.8 standard deviations
below
the category average. This places PSIL in the 1st percentile among funds in the category.
Sell Side Consensus Rating
Sell-side recommendations on the ETF's individual constituents
PSILSELL
U/W
HOLD
O/W
BUY
Expense Analysis
| Peer Group | Active International Equity ETFs |
| # of ETFs | 38 |
| Avg. Expense Ratio | 56.2 bp |
| Std. Deviation | 24 bp |
| PSIL (99 bp) Percentile rank | 96 |
Peer Group Expense Ratio Distribution
Total Cost of Ownership (TCO) Comparison
| Expense (bp) (A) |
Avg. Bid/Ask (bp) (B) |
TCO (bp) (A)+(B) |
|
|---|---|---|---|
| PSIL | 99.0 | 144.3 | 243.3 |
| Peer Avg. | 67.8 | 51.0 | 118.8 |
For a detailed cost analysis of this and any other ETF use the TCO Comparison Tool .